参考文献/References:
[1] Guha S,Bhaumik SR.Transcription-coupled DNA double-strand break repair[J].DNA Repair(Amst),2022,109:103211.
[2] Libri A,Marton T,Deriano L.The(lack of)DNA double-strand break repair pathway choice during V(D)J recombination[J].Frontiers in Genetics,2022,12:823943.
[3] Xu Y,Xu D.Repair pathway choice for double-strand breaks[J].Essays Biochem,2020,64(5):765-777.
[4] Abdallah R,Zhao S,Garinet S,et al.BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma[J].Clin Res Hepatol Gastroenterol,2022,46(5):101880.
[5] Carley AC,Jalan M,Subramanyam S,et al.Replication protein A phosphorylation facilitates RAD52-dependent homologous recombination in BRCA-deficient cells[J].Mol Cell Biol,2022,42(2):e52421.
[6] Deveryshetty J,Rau M,Fitzpatrick JAJ,et al.Allostery of RAD52 during pre-synapsis complex assembly in homologous recombination mediated repair[J].Biophysical Journal,2022,121(3):447.
[7] Wang T,Du XH,Hong Y,et al.WASH interacts with Ku to regulate DNA double-stranded break repair[J].Iscience,2022,25(1):103676.
[8] Anisenko A,Shadrina O,Garanina I,et al.Transcriptome dataset of HEK293T cells depleted of one of the subunits of the DNA-PK complex:Ku70,Ku80 or DNA-PKcs[J].Data Brief,2021,39:107596.
[9] Liu L,Chen X,Li J,et al.Autophosphorylation transforms DNA-PK from protecting to processing DNA ends[J].Mol Cell,2022,82(1):177-189.
[10] Koike M,Yutoku Y,Koike A.Feline XRCC4 undergoes rapid Ku-dependent recruitment to DNA damage sites.[J].FEBS Open Bio,2022,12(4):798-810.
[11] Francis DB,Kozlov M,Chavez J,et al.DNA ligase Ⅳ regulates XRCC4 nuclear localization[J].DNA Repair(Amst),2014,21:36-42.
[12] Tang J,Li Z,Wu Q,et al.Role of paralogue of XRCC4 and XLF in DNA Damage repair and cancer development[J].Front Immunol,2022,13:852453.
[13] Gago-Fuentes R,Oksenych V.Non-homologous end joining factors XLF,PAXX and DNA-PKcs maintain the neural stem and progenitor cell population[J].Biomolecules,2020,11(1):20.
[14] Zimmermann M,Oehler C,Mey U,et al.Radiotherapy for non-Hodgkin's lymphoma:Still standard practice and not an outdated treatment option[J].Radiation Oncology(London,England),2016,11(1):110.
[15] Vidya G,Gudapureddy R,Sathees CR,et al.Inhibitor of nonhomologous end joining can inhibit proliferation of diffuse large B-cell lymphoma cells and potentiate the effect of ionization radiation[J].Journal of Radiation and Cancer Research,2018,9(2):93-101.
[16] Sishc BJ,Davis AJ.The role of the core non-homologous end joining factors in carcinogenesis and cancer[J].Cancers(Basel),2017,9(7):81.
[17] Srivastava M,Nambiar M,Sharma S,et al.An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression[J].Cell,2012,151(7):1474-1487.
[18] Vartak SV,Swarup HA,Gopalakrishnan V.Autocyclized and oxidized forms of SCR7 induce cancer cell death by inhibiting nonhomologous DNA end joining in a Ligase Ⅳ dependent manner[J].FEBS J,2018,285(21):3959-3976.
[19] Ray U,Vartak SV,Raghavan SC.NHEJ inhibitor SCR7 and its different forms:Promising CRISPR tools for genome engineering[J].Gene,2020,763:144997.
[20] Monica P,Vidya G,Hassan AS,et al.Water-soluble version of SCR7-pyrazine inhibits DNA repair and abrogates tumor cell proliferation[J].Journal of Radiation and Cancer Research,2019,10(1):27-43.
[21] Ray U,Raul SK,Gopinatha VK,et al.Identification and characterization of novel SCR7-based small-molecule inhibitor of DNA end-joining,SCR130 and its relevance in cancer therapeutics[J].Mol Carcinog,2020,59(6):618-628.
[22] Gopalakrishnan V,Sharma S,Ray U,et al.SCR7,an inhibitor of NHEJ can sensitize tumor cells to ionization radiation[J].Mol Carcinog,2021,60(9):627-643.
[23] Kopa P,Macieja A,Pastwa E,et al.DNA double-strand breaks repair inhibitors potentiates the combined effect of VP-16 and CDDP in human colorectal adenocarcinoma(LoVo)cells[J].Mol Biol Rep,2021,48(1):709-720.
[24] Berardinelli GN,Scapulatempo-Neto C,Duraes R,et al.Advantage of HSP110(T17)marker inclusion for microsatellite instability(MSI)detection in colorectal cancer patients[J].Oncotarget,2018,9(47):28691-28701.
[25] Robert F,Barbeau M,Ethier S,et al.Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing[J].Genome Med,2015,7:93.
[26] Maruyama T,Dougan SK,Truttmann MC,et al.Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining[J].Nat Biotechnol,2015,33(5):538-542.
[27] Li G,Zhang X,Zhong C,et al.Small molecules enhance CRISPR/Cas9-mediated homology-directed genome editing in primary cells[J].Sci Rep,2017,7(1):8943.
[28] Gkotzamanidou M,Terpos E,Bamia C,et al.DNA repair of myeloma plasma cells correlates with clinical outcome:The effect of the nonhomologous end-joining inhibitor SCR7[J].Blood,2016,128(9):1214-1225.
[29] Tseng HM,Shum D,Bhinder B,et al.A high-throughput scintillation proximity-based assay for human DNA ligase Ⅳ[J].Assay Drug Dev Technol,2012,10(3):235-249.